{
    "info": {
        "nct_id": "NCT05109442",
        "official_title": "A Phase 1/2a Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AFM24 in Combination with Atezolizumab in Patients with Selected Advanced/Metastatic EGFR-expressing Cancers",
        "inclusion_criteria": "* Histologically or cytologically confirmed advanced or metastatic EGFR-positive selected cancer types (except for NSCLC)\n* Advanced or metastatic NSCLC, EGFR WT: disease has progressed after ≥ 1 prior lines of therapy which must have included a platinum-based doublet in combination with PD1/PD-L1 antibody or must have received an anti-PD1/PD-L1 antibody prior to or after a platinum-based doublet\n* Advanced, unresectable, or metastatic gastric/GEJ adenocarinoma: after ≥ 1 prior chemotherapy regimen including a platinum and fluoropyrimidine doublet\n* Advanced or metastatic HCC (BCLC C or B not amenable or refractory to locoregional therapy), hepatobiliary-, or pancreatic adenocarcinoma: after ≥1 prior line of an approved SOC therapy for the respective disease type or to whom the available SOC is not appropriate in the opinion of the investigator\n* Advanced or metastatic NSCLC harboring a targetable EGFR kinase domain mutation and whose disease has progressed on or after having received ≥ prior TKI approved for EGFR mutated NSCLC. Subjects trated with a 1st or 2nd generation TKI in 1st line who developed a documented T790M mutation must have received a TKI targeting this mutation such as Osimertinib or Lazertinib to be eligible. Subjects must have documentation of EGFR mutated NSCLC as assessed by an approved test using genomic sequencing of tumor or circulation free tumor DNA. The patients should have received a 2nd line of treatment if approved and available or may be enrolled in the study if in the opinion of the investigator it is in the patient's best interest,or the SOC is not appropriate.\n* Adequate organ function\n* Phase 1: Evaluable or measurable disease per RECIST v1.1\n* Phase 2a: Measurable disease per RECIST v1.1\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Treatment with systemic anticancer therapy including investigational agent within 4 weeks of the first dose of study drug, 6 weeks for mitomycin C or nitrosoureas, 2 weeks (or 5 half-lives whichever is longer) for using fluorouracil or small molecule targeted drugs, 2 weeks for using traditional Chinese medicine with anti-tumor indication.\n* Radiation therapy within 2 weeks before 1st dose of study drug or unresolved toxicity from previous radiotherapy\n* History of any other malignancy known to be active, with the exception of completely removed in situ cervical intra-epithelial neoplasia, non-melanoma skin cancer, DCIS, early stage prostate cancer that has been adequately treated, and other cancers from which the patient has been disease free for 3 years or longer\n* Currently active in any other clinical study, or administration of other investigational agent",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Phase 2a: Measurable disease per RECIST v1.1",
            "criterions": [
                {
                    "exact_snippets": "Measurable disease per RECIST v1.1",
                    "criterion": "disease measurability",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "assessment_criteria",
                            "expected_value": "RECIST v1.1"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically or cytologically confirmed advanced or metastatic EGFR-positive selected cancer types (except for NSCLC)",
            "criterions": [
                {
                    "exact_snippets": "Histologically or cytologically confirmed",
                    "criterion": "cancer diagnosis confirmation method",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histologically",
                                "cytologically"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "advanced or metastatic",
                    "criterion": "cancer stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "advanced",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "EGFR-positive",
                    "criterion": "EGFR status",
                    "requirements": [
                        {
                            "requirement_type": "EGFR expression",
                            "expected_value": "positive"
                        }
                    ]
                },
                {
                    "exact_snippets": "selected cancer types (except for NSCLC)",
                    "criterion": "cancer type",
                    "requirements": [
                        {
                            "requirement_type": "cancer type inclusion",
                            "expected_value": "selected cancer types"
                        },
                        {
                            "requirement_type": "cancer type exclusion",
                            "expected_value": "NSCLC"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate organ function",
            "criterions": [
                {
                    "exact_snippets": "Adequate organ function",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Advanced, unresectable, or metastatic gastric/GEJ adenocarinoma: after ≥ 1 prior chemotherapy regimen including a platinum and fluoropyrimidine doublet",
            "criterions": [
                {
                    "exact_snippets": "Advanced, unresectable, or metastatic gastric/GEJ adenocarinoma",
                    "criterion": "gastric/GEJ adenocarcinoma",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "advanced",
                                "unresectable",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "after ≥ 1 prior chemotherapy regimen",
                    "criterion": "prior chemotherapy regimens",
                    "requirements": [
                        {
                            "requirement_type": "number",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "regimen"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "including a platinum and fluoropyrimidine doublet",
                    "criterion": "prior chemotherapy regimen components",
                    "requirements": [
                        {
                            "requirement_type": "components",
                            "expected_value": [
                                "platinum",
                                "fluoropyrimidine doublet"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Advanced or metastatic HCC (BCLC C or B not amenable or refractory to locoregional therapy), hepatobiliary-, or pancreatic adenocarcinoma: after ≥1 prior line of an approved SOC therapy for the respective disease type or to whom the available SOC is not appropriate in the opinion of the investigator",
            "criterions": [
                {
                    "exact_snippets": "Advanced or metastatic HCC (BCLC C or B not amenable or refractory to locoregional therapy)",
                    "criterion": "hepatocellular carcinoma (HCC)",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "advanced",
                                "metastatic"
                            ]
                        },
                        {
                            "requirement_type": "BCLC stage",
                            "expected_value": [
                                "C",
                                "B"
                            ]
                        },
                        {
                            "requirement_type": "amenability to locoregional therapy",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "refractory to locoregional therapy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hepatobiliary-, or pancreatic adenocarcinoma",
                    "criterion": "hepatobiliary or pancreatic adenocarcinoma",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "after ≥1 prior line of an approved SOC therapy for the respective disease type",
                    "criterion": "prior lines of approved standard of care (SOC) therapy",
                    "requirements": [
                        {
                            "requirement_type": "number of prior lines",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "line"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "to whom the available SOC is not appropriate in the opinion of the investigator",
                    "criterion": "appropriateness of available standard of care (SOC) therapy",
                    "requirements": [
                        {
                            "requirement_type": "appropriateness for SOC",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Advanced or metastatic NSCLC, EGFR WT: disease has progressed after ≥ 1 prior lines of therapy which must have included a platinum-based doublet in combination with PD1/PD-L1 antibody or must have received an anti-PD1/PD-L1 antibody prior to or after a platinum-based doublet",
            "criterions": [
                {
                    "exact_snippets": "Advanced or metastatic NSCLC",
                    "criterion": "NSCLC disease stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "advanced",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "EGFR WT",
                    "criterion": "EGFR mutation status",
                    "requirements": [
                        {
                            "requirement_type": "mutation status",
                            "expected_value": "wild-type"
                        }
                    ]
                },
                {
                    "exact_snippets": "disease has progressed after ≥ 1 prior lines of therapy",
                    "criterion": "prior lines of therapy and disease progression",
                    "requirements": [
                        {
                            "requirement_type": "number of prior lines of therapy",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lines"
                            }
                        },
                        {
                            "requirement_type": "disease progression",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "which must have included a platinum-based doublet in combination with PD1/PD-L1 antibody",
                    "criterion": "prior therapy regimen",
                    "requirements": [
                        {
                            "requirement_type": "prior therapy",
                            "expected_value": [
                                "platinum-based doublet",
                                "PD1/PD-L1 antibody",
                                "combination"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "or must have received an anti-PD1/PD-L1 antibody prior to or after a platinum-based doublet",
                    "criterion": "sequence of prior therapies",
                    "requirements": [
                        {
                            "requirement_type": "prior therapy sequence",
                            "expected_value": "anti-PD1/PD-L1 antibody before or after platinum-based doublet"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Advanced or metastatic NSCLC harboring a targetable EGFR kinase domain mutation and whose disease has progressed on or after having received ≥ prior TKI approved for EGFR mutated NSCLC. Subjects trated with a 1st or 2nd generation TKI in 1st line who developed a documented T790M mutation must have received a TKI targeting this mutation such as Osimertinib or Lazertinib to be eligible. Subjects must have documentation of EGFR mutated NSCLC as assessed by an approved test using genomic sequencing of tumor or circulation free tumor DNA. The patients should have received a 2nd line of treatment if approved and available or may be enrolled in the study if in the opinion of the investigator it is in the patient's best interest,or the SOC is not appropriate.",
            "criterions": [
                {
                    "exact_snippets": "Advanced or metastatic NSCLC",
                    "criterion": "NSCLC stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "advanced",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "NSCLC harboring a targetable EGFR kinase domain mutation",
                    "criterion": "EGFR kinase domain mutation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "targetability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "disease has progressed on or after having received ≥ prior TKI approved for EGFR mutated NSCLC",
                    "criterion": "prior TKI therapy for EGFR mutated NSCLC",
                    "requirements": [
                        {
                            "requirement_type": "number of prior TKI therapies",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "TKI"
                            }
                        },
                        {
                            "requirement_type": "disease progression after TKI",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Subjects trated with a 1st or 2nd generation TKI in 1st line who developed a documented T790M mutation must have received a TKI targeting this mutation such as Osimertinib or Lazertinib",
                    "criterion": "T790M mutation and subsequent TKI therapy",
                    "requirements": [
                        {
                            "requirement_type": "T790M mutation after 1st/2nd gen TKI",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "received TKI targeting T790M",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "documentation of EGFR mutated NSCLC as assessed by an approved test using genomic sequencing of tumor or circulation free tumor DNA",
                    "criterion": "EGFR mutation documentation",
                    "requirements": [
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "assessment method",
                            "expected_value": [
                                "approved test using genomic sequencing of tumor",
                                "circulation free tumor DNA"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "patients should have received a 2nd line of treatment if approved and available or may be enrolled in the study if in the opinion of the investigator it is in the patient's best interest,or the SOC is not appropriate",
                    "criterion": "2nd line treatment or investigator decision",
                    "requirements": [
                        {
                            "requirement_type": "received 2nd line treatment if approved and available",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "investigator discretion if 2nd line not received",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "SOC appropriateness",
                            "expected_value": "not appropriate"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Phase 1: Evaluable or measurable disease per RECIST v1.1",
            "criterions": [
                {
                    "exact_snippets": "Evaluable or measurable disease per RECIST v1.1",
                    "criterion": "disease status",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "evaluable",
                                "measurable"
                            ]
                        },
                        {
                            "requirement_type": "assessment_criteria",
                            "expected_value": "RECIST v1.1"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Treatment with systemic anticancer therapy including investigational agent within 4 weeks of the first dose of study drug, 6 weeks for mitomycin C or nitrosoureas, 2 weeks (or 5 half-lives whichever is longer) for using fluorouracil or small molecule targeted drugs, 2 weeks for using traditional Chinese medicine with anti-tumor indication.",
            "criterions": [
                {
                    "exact_snippets": "Treatment with systemic anticancer therapy including investigational agent within 4 weeks of the first dose of study drug",
                    "criterion": "systemic anticancer therapy (including investigational agent)",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "6 weeks for mitomycin C or nitrosoureas",
                    "criterion": "mitomycin C or nitrosoureas treatment",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "2 weeks (or 5 half-lives whichever is longer) for using fluorouracil or small molecule targeted drugs",
                    "criterion": "fluorouracil or small molecule targeted drugs treatment",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": [
                                "2 weeks",
                                "5 half-lives (whichever is longer)"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "2 weeks for using traditional Chinese medicine with anti-tumor indication",
                    "criterion": "traditional Chinese medicine with anti-tumor indication",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Radiation therapy within 2 weeks before 1st dose of study drug or unresolved toxicity from previous radiotherapy",
            "criterions": [
                {
                    "exact_snippets": "Radiation therapy within 2 weeks before 1st dose of study drug",
                    "criterion": "radiation therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last radiation therapy",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unresolved toxicity from previous radiotherapy",
                    "criterion": "toxicity from previous radiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "resolution status",
                            "expected_value": "resolved"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of any other malignancy known to be active, with the exception of completely removed in situ cervical intra-epithelial neoplasia, non-melanoma skin cancer, DCIS, early stage prostate cancer that has been adequately treated, and other cancers from which the patient has been disease free for 3 years or longer",
            "criterions": [
                {
                    "exact_snippets": "History of any other malignancy known to be active",
                    "criterion": "other active malignancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "completely removed in situ cervical intra-epithelial neoplasia, non-melanoma skin cancer, DCIS, early stage prostate cancer that has been adequately treated, and other cancers from which the patient has been disease free for 3 years or longer",
                    "criterion": "history of specific prior cancers",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "completely removed in situ cervical intra-epithelial neoplasia",
                                "non-melanoma skin cancer",
                                "DCIS",
                                "early stage prostate cancer that has been adequately treated",
                                "other cancers from which the patient has been disease free for 3 years or longer"
                            ]
                        },
                        {
                            "requirement_type": "exclusion",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Currently active in any other clinical study, or administration of other investigational agent",
            "criterions": [
                {
                    "exact_snippets": "Currently active in any other clinical study",
                    "criterion": "participation in other clinical study",
                    "requirements": [
                        {
                            "requirement_type": "current activity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "administration of other investigational agent",
                    "criterion": "administration of other investigational agent",
                    "requirements": [
                        {
                            "requirement_type": "current administration",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}